Clinical Trial Detail

NCT ID NCT03061188
Title Nivolumab and Veliparib in Treating Patients With Recurrent or Refractory Stage IV Solid Tumors That Cannot Be Removed by Surgery or Lymphoma With or Without Alterations in DNA Repair Genes
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Northwestern University
Indications

Advanced Solid Tumor

lymphoma

Therapies

Nivolumab + Veliparib

Age Groups: adult senior

Additional content available in CKB BOOST